Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced the Nomination Committee’s proposal for a new Board of Directors that will be submitted to the 2015 Annual General Meeting. The 2014-2015 Nomination Committee comprises representatives of the company’s three largest shareholders at the end of the third quarter of 2014 who have accepted a seat on the Nomination Committee, and the Chairman of the Board. The composition of the 2014-2015 Nomination Committee was as follows:
- Anders Algotsson, Chairman of the Nomination Committee, representing AFA Försäkring
- Maria Rengefors, representing Nordea Fonder
- Birgitta Stymne Göransson, Chairman of the Board of Medivir AB
- Bo Öberg, representing the class A shareholders
The Nomination Committee has agreed, ahead of the upcoming 2015 Annual General Meeting, to propose that a new Board of Directors be appointed by means of the re-election of the Board’s existing Members, namely Anna Malm Bernsten, Anders Ekblom, Anders Hallberg, Bertil Samuelsson and Birgitta Stymne Göransson, and the new election of two Members, namely Johan Harmenberg and Helena Levander. The Committee also proposes the re-election of Birgitta Stymne Göransson as Chairman of the Board.
Björn C. Andersson has declined re-election and Niklas Prager resigned his seat on the Board in September 2014 in conjunction with his appointment as President & CEO of the company.
Johan Harmenberg, born 1954, is a physician, Doctor of Medicine, and an Associate Professor of Virology at the Karolinska Institute, and has conducted scientific research work at MIT in Cambridge, Mass., USA. Johan is currently the Chief Medical Officer of Glionova AB and Oncopeptides AB, and has previously worked as a researcher, Chief Medical Officer, and Development Manager at, amongst others, Roche, Astra, Pharmacia & Upjohn, Medivir and Algeta ASA. Johan is also a former CEO of Axelar AB and Akinion AB and Member of the Boards of Light-up AB and Oxypharma AB. He has published over 100 scientific papers and abstracts, mainly on pharmaceuticals and the development of pharmaceuticals for the treatment of cancer and infectious diseases.
Helena Levander, born 1957, gained a degree in Business Administration from the Stockholm School of Economics. Helena is a founder and Chairman of the Board of Nordic Investor Services AB and has extensive experience of corporate governance issues. Helena has previously worked for companies such as Neonet, Odin Förvaltning, Nordea Asset Management and SEB Asset Management. She is a Member of the Boards of Concordia Maritime AB, Hans Andersson Recycling AB, NeuroVive Pharmaceutical AB, Collector AB, Uniflex Bemanning AB and Stampen AB, and a former Member of the Boards of a number of companies, including Gant AB, Transatlantic AB, Nordisk Energiforvaltning ASA, Svensk Exportkredit AB (SEK), Bure Equity AB, Mandator AB, Geveko AB, Erik Penser Bankaktiebolag and SBAB Bank AB.
For further information, please contact:
Anders Algotsson, AFA Försäkring +46 (8) 696 40 67
About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.